Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

TKIs for Advanced HCC in the Second Line and Beyond

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the role of tyrosine kinase inhibitors in treating patients with advanced HCC in the second line and beyond.
Josep M. Llovet, MD
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA
Released: February 22, 2022

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include:

  • Available agents for the management of advanced hepatocellular carcinoma in the second line
  • The current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinoma
  • Ongoing clinical trials in the second-line setting

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Information on this Educational Activity

Faculty

Josep M. Llovet, MD

Professor of Medicine
Director,
Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
Professor of Research
Liver Unit, IDIBAPS
Hospital Clínic Barcelona
Barcelona, Spain

Josep M. Llovet, MD, PhD, FAASLD, has disclosed that he receives funds for contracted research from Bayer HealthCare Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Eisai, and Ipsen Pharma and consulting fees from Bayer Healthcare Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Celson Corporation, Eisai, Eli Lilly, Exelixis, Ipsen Pharma, and Merck.
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA

Professor of Medicine
Medical University of Vienna
Vienna, Austria
Department Chair
Innere Medizin und Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Markus Peck-Radosavljevic, MD, MBA, has disclosed that he receives consulting fees from Bayer HealthCare Pharmaceuticals, Eisai, Gilead Sciences, Ipsen, Lily, and Roche and fees for non-CME/CE services from Bayer Healthcare, Bristol Myers Squibb, Eisai, Gilead Sciences, Ipsen, Lilly, MSD, and Roche.

Program Medium

This program has been made available online.

Related Content

Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 6, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022

Clinical Care Options (CCO): Experts review key data for gastric, rectal, liver, hepatobiliary tract, and pancreas cancers from the 2022 ASCO Gastrointestinal Cancers Symposium and the ASCO Plenary Series

Manish A. Shah, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 20, 2022 Expired: April 19, 2023

Experts discuss the use of immunotherapy for HCC in this commentary from Clinical Care Options (CCO)

person default Adam Burgoyne, MD, PhD Lipika Goyal, MD Stacey Stein, MD Released: March 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings